Point72 Asset Management L.P. Cuts Position in UroGen Pharma Ltd. (NASDAQ:URGN)

Point72 Asset Management L.P. cut its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 38.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,506,646 shares of the company's stock after selling 942,631 shares during the period. Point72 Asset Management L.P. owned 6.42% of UroGen Pharma worth $19,134,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Great Point Partners LLC grew its position in UroGen Pharma by 10.9% during the 2nd quarter. Great Point Partners LLC now owns 2,906,259 shares of the company's stock worth $48,767,000 after purchasing an additional 285,714 shares during the last quarter. Cowen AND Company LLC lifted its stake in shares of UroGen Pharma by 29.1% during the second quarter. Cowen AND Company LLC now owns 2,099,482 shares of the company's stock worth $35,229,000 after buying an additional 472,893 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of UroGen Pharma by 1.6% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,341,072 shares of the company's stock valued at $17,032,000 after buying an additional 21,072 shares during the last quarter. Millennium Management LLC increased its position in shares of UroGen Pharma by 2,672.0% in the 2nd quarter. Millennium Management LLC now owns 1,160,899 shares of the company's stock valued at $19,480,000 after acquiring an additional 1,119,019 shares during the period. Finally, Vestal Point Capital LP purchased a new position in UroGen Pharma in the 3rd quarter worth $5,080,000. Hedge funds and other institutional investors own 91.29% of the company's stock.

Wall Street Analyst Weigh In

URGN has been the topic of several research analyst reports. Oppenheimer reiterated an "outperform" rating and set a $40.00 price target on shares of UroGen Pharma in a research note on Wednesday, October 16th. HC Wainwright reiterated a "buy" rating and issued a $60.00 target price on shares of UroGen Pharma in a research report on Tuesday, October 15th. Guggenheim assumed coverage on shares of UroGen Pharma in a research report on Thursday, August 22nd. They set a "buy" rating and a $40.00 price target for the company. EF Hutton Acquisition Co. I raised shares of UroGen Pharma to a "strong-buy" rating in a report on Monday, October 14th. Finally, D. Boral Capital reiterated a "buy" rating and issued a $25.00 price objective on shares of UroGen Pharma in a research note on Friday. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $43.70.

UroGen Pharma Price Performance

UroGen Pharma stock traded up $0.08 during midday trading on Friday, hitting $12.29. 309,244 shares of the company were exchanged, compared to its average volume of 393,930. UroGen Pharma Ltd. has a fifty-two week low of $10.60 and a fifty-two week high of $20.70. The business has a fifty day simple moving average of $12.28 and a two-hundred day simple moving average of $13.96. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.55) EPS for the quarter, topping analysts' consensus estimates of ($0.84) by $0.29. The firm had revenue of $25.20 million for the quarter, compared to analyst estimates of $24.22 million. During the same period in the previous year, the business earned ($0.68) EPS. Research analysts forecast that UroGen Pharma Ltd. will post -3.1 earnings per share for the current year.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.